Références

ALDURAZYME [insérer emballage]. Novato, Californie : BioMarin Pharmaceutical Inc ; 2013.

All about the Human Genome Project. Site web du National Human Genome Research Institute. https://www.genome.gov/10001772/all-about-the-human/genome-project-hgp. Mis à jour le 1er octobre 2015. Consulté le 11 septembre 2018.

ASH Clinical News. Researchers report first successful gene therapy for hemophilia A. Site web de l’American Society of Hematology. https://www.ashclinicalnews.org/on-location/researchers-report-first-successful-gene-therapy-hemophilia/. Consulté le 11 septembre 2018.

Brineura [insérer emballage]. Novato, Californie : BioMarin Pharmaceutical Inc;2018.

Current trends update: acquired immunodeficiency syndrome (AIDS) among patients with hemophilia—United States. Site web des Centers for Disease Control. https://www.cdc.gov/mmwr/preview/mmwrhtml/00000181.htm. Consulté le 11 septembre 2018.

Franklin RE, Gosling RG. Molecular configuration in sodium thymonucleate. Nature.1953;171(4356):740-741.

Gene therapy—a revolution in progress: human genetics and medical research. Site web des National Institutes of Health. https://history.nih.gov/exhibits/genetics/sect4.htm. Consulté le 11 septembre 2018.

Genetic timeline. Site web du National Human Genome Research Institute. https://www.genome.gov/pages/education/genetictimeline.pdf. Consulté le 11 septembre 2018.

Giangrande P. The future of hemophilia treatment: longer-acting factor concentrates versus gene therapy. Semin Thromb Hemost. 2016 ; 42 (5) : 513-517.

Gregor Mendel: the father of modern genetics. Site web de l’Office of NIH History. https://history.nih.gov/exhibits/nirenberg/HS1_mendel.htm. Consulté le 11 septembre 2018.

Hemophilia: from plasma to recombinant factors. Site web de l’American Society of Hematology. http://www.hematology.org/About/History/50-Years/1524.aspx. Consulté le 11 septembre 2018.

Highlights of transfusion medicine history. Site web de l’AABB. http://www.aabb.org/tm/Pages/highlights.apx. Consulté le 11 septembre 2018.

History. Site web de BioMarin. http://www.biomarin.com/about/history/#1997. Consulté le 11 septembre 2018.

History of bleeding disorders. Site web de la National Hemophilia Foundation. https://www.hemophilia.org/Bleeding-Disorders/History-of-Bleeding-Disorders. Consulté le 11 septembre 2018.

Hoffman M.FVIIa:you’ve come a long way,baby! Blood.2008;112(8):3002-3003.

KUVAN[insérer emballage].Novato, Californie:BioMarin Pharmaceutical Inc ;2016.

Manno CS, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med.2006;12(3):342-347.

Morfini M, Coppola A, Franchini M, Di Minno G. Clinical use of factor VIII and factor IX concentrates. Blood Transfus.2013;11(suppl.4):s55-s63.

NAGLAZYME [insérer emballage]. Novato, Californie : BioMarin Pharmaceutical Inc;2013.

Ng HJ, Lee LH. Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients. Vasc Health Risk Manag.2006;2(4):433-440.

Powell JS. Longer-acting clotting factor concentrates for hemophilia. J Thromb Haemost.2015;13(suppl. 1):S167-S175.

Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia.2013;19 (1):e1-e47.

Tratschin J-D, West MH, Sandbank T, Carter BJ.A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol.1984;4(10):2072-2 081.

VIMIZIM [insérer emballage]. Novato, Californie : BioMarin Pharmaceutical Inc;2014.

Watson JD, Crick FH. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature.1953;171(4 356):737-738.

Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature.1984;312(5992):330-337.